Amarin Corporation

Update in progress

AMRN (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryDrug Manufacturers - General

Amarin Corporation plc is a pharmaceutical company focused on developing and commercializing cardiovascular therapies in the United States, Europe, and beyond. It markets Vascepa, a prescription omega-3 fatty acid used with diet to reduce triglycerides in adults with severe hypertriglyceridemia. Products are sold mainly through wholesalers and pharmacies. It collaborates with Mochida to develop and commercialize EPA-based products. Formerly Ethical Holdings plc; renamed in 1999. Established 1989, based in Dublin, Ireland.

Company score

Sentiment: -0.11; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.00; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.15; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: -0.03; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: -0.07; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive

Company

MarketNasdaqCM (NCM)
LocationIreland
CEOMr. Aaron D. Berg
Founded1989
Employees80
Websitewww.amarincorp.com

Identifiers

ISINUS0231114044
FIGIBBG000BPYG99
CUSIP023111107
CIK0001120246